Logo

NAOV

NanoVibronix, Inc.

NAOV

NanoVibronix, Inc. • NASDAQ
$4.13 ▼ -1.67% (-0.07)
Market Cap $3.29 M
52w High $162.50
52w Low $3.55
Dividend Yield 0%
P/E -0.08
Volume 12.55K
Outstanding Shares 796.91K

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $722K ▲ $2.436M ▼ $510K ▲ 70.637% ▲ $1.05 ▲ $855K ▲
Q2-2025 $494K ▼ $3.941M ▲ $-156K ▲ -31.579% ▲ $-1.03 ▲ $-3.401M ▼
Q1-2025 $1.025M ▲ $2.221M ▲ $-2.495M ▼ -243.415% ▲ $-3.98 ▲ $-2.409M ▼
Q4-2024 $444K ▲ $1.653M ▲ $-1.431M ▼ -322.297% ▼ $-4.21 ▼ $-1.392M ▼
Q3-2024 $376K $1.103M $-998K -265.426% $-3.6 $-962K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $6.95M ▲ $54.383M ▲ $11.919M ▲ $42.464M ▲
Q2-2025 $4.03M ▲ $51.482M ▲ $11.005M ▲ $40.477M ▲
Q1-2025 $601K ▼ $44.105M ▲ $8.43M ▲ $35.675M ▲
Q4-2024 $752K ▼ $3.629M ▼ $3.002M ▲ $627K ▼
Q3-2024 $1.305M $4.682M $2.81M $1.872M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $600K ▲ $-1.97M ▲ $-28K ▼ $4.92M ▼ $2.92M ▼ $-1.998M ▲
Q2-2025 $-3.348M ▼ $-3.383M ▼ $-4K ▼ $6.85M ▲ $3.459M ▲ $-3.387M ▼
Q1-2025 $-2.495M ▼ $-1.343M ▼ $143K ▲ $1.05M ▲ $-151K ▲ $-1.348M ▼
Q4-2024 $-1.431M ▼ $-548K ▲ $0 $0 ▲ $-553K ▲ $-548K ▲
Q3-2024 $-998K $-836K $0 $-27K $-865K $-836K

Five-Year Company Overview

Income Statement

Income Statement The income statement points to a company that is still very much in the development and commercialization phase. Reported revenue is essentially nonexistent in the data provided, which suggests limited or very early-stage sales. At the same time, the company has been consistently unprofitable, with large losses per share indicating that expenses meaningfully exceed any revenue being generated. In plain terms, this looks like a business that is still trying to turn promising technology into a scalable commercial model, and has not yet shown a clear path to operating profitability.

Balance Sheet

Balance Sheet The balance sheet appears very thin, with only a small base of assets and equity and essentially no debt. The lack of debt removes one form of financial risk, but the very small scale of assets and equity also signals a fragile financial position and limited cushion to absorb ongoing losses. Cash balances look modest, suggesting that the company likely depends on periodic capital raises to fund operations. Multiple reverse stock splits in recent years further hint at a history of share issuance and efforts to maintain exchange listing standards, which is common for small, loss-making companies but still a key risk flag.

Cash Flow

Cash Flow Cash flow data reinforces the picture of a company that consumes, rather than generates, cash. Operating cash flow has been negative, albeit at a relatively small absolute scale, which is consistent with a development‑stage medical device firm investing in commercialization and R&D before meaningful revenue arrives. With little capital spending reported, most cash usage seems tied to ongoing operating and development costs. The company’s ability to keep going likely depends on access to external financing, so future capital raises and dilution are important considerations when thinking about its cash flow profile.

Competitive Edge

Competitive Edge NanoVibronix operates in a very competitive healthcare and medical device landscape but targets a narrower niche with its therapeutic ultrasound and surface acoustic wave technology. Its differentiation comes from non‑invasive, drug‑free, portable devices designed for home and bedside use, which aligns with healthcare trends toward outpatient and at‑home care. However, as a small player, it faces significant hurdles: building physician and patient awareness, securing reimbursement, competing against established pain management, wound care, and infection‑prevention solutions, and navigating regulatory requirements. The company’s patent portfolio and specialized focus provide some protection, but commercial execution and market adoption remain the key unknowns.

Innovation and R&D

Innovation and R&D Innovation is clearly the company’s main strength. Its core surface acoustic wave platform underpins a family of devices for pain relief, wound healing, and infection prevention on catheters and feeding tubes. Products like PainShield, UroShield, NG‑Shield, and WoundShield showcase how one technology can be adapted across several clinical problems, while the ENvue navigation system extends the reach into medical imaging and device placement. On top of this, pipeline ideas such as Renooskin for cosmetic use and the ENvue Drive robotic platform for automated navigation illustrate an ambition to expand into both aesthetics and advanced hospital technologies. The company is also active in building and extending its patent estate. The flip side is that this innovation engine is costly and has not yet translated into substantial, proven commercial scale, so there is a wide gap between technical promise and financial results.

Summary

Overall, NanoVibronix looks like an early‑stage, innovation‑driven medical device company with a strong emphasis on proprietary technology but very limited demonstrated financial traction so far. The financial statements point to minimal revenue, ongoing losses, and a very small capital base supported by external financing rather than internal cash generation. On the positive side, the firm has a distinct technology platform, a growing product lineup, and a broad patent portfolio that could support multiple applications in pain management, wound care, infection control, navigation, and even aesthetics. On the risk side, it still needs to prove it can convert this technology into sustainable sales, manage regulatory and reimbursement pathways, and operate with enough financial resilience to reach scale. In short, the story is heavy on innovation potential and light on established financial performance, which makes execution over the next few years especially critical.

NEWS

November 19, 2025 · 8:00 AM UTC

NanoVibronix Issues Letter to Shareholders

Read more

September 18, 2025 · 8:00 AM UTC

NanoVibronix Launches “Oscar” Training Aid to Accelerate ENvue Adoption and Unlock New Revenue Opportunities

Read more

September 16, 2025 · 3:57 PM UTC

NanoVibronix Announces Pricing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Read more

September 15, 2025 · 8:00 AM UTC

NanoVibronix Announces Grant of New U.S. Patent Further Expanding ENvue Medical’s Intellectual Property Portfolio

Read more

September 4, 2025 · 8:00 AM UTC

NanoVibronix Announces U.S. Patent Granted to ENvue Medical for Real-Time Imaging Overlay in Navigation Technology

Read more